‘Destiny 2' Reveals Next Four ‘Fate Saga' Expansions, New ‘Edge Of Fate' Details
Destiny 2 Bungie
The new Destiny 2 saga after Light and Darkness is officially called The Fate Saga, which begins with The Edge of Fate on July 15. Bungie also announced the upcoming four expansions in total, The Edge of Fate, Renegade in December 2025, Shattered Cycle in summer 2026 and The Alchemist in winter 2026. The saga will explore the nature of fate and the foundations of the universe itself. It's focused on the Nine, who we learn are actually nine individual beings with their own personalities, goals and rivalries. They are heavily involved in our solar system and this saga does not appear to be leaving our solar system as previously forecast.
The first destination is Kepler, which is not an out-of-solar system planet like it is in real life, but a Nine-infused place at the edge of our system. Vex are there to study the Nine, Fallen are there too. Vex have new units called Kobolds, Fallen have flying corsairs. People have been there for a long time including new Gordon Freeman-looking guy, Koda(sp?). Ikora is the main returning exiting NPC.
Destiny 2 Bungie There is a gameplay trailer repeating SIVA directives over and over, though I did not see many other SIVA hints there. Would be odd if it was not involved, given that.
There are now World Tiers in zones for better loot farming and harder challenges. Gear also has a new tier system with higher content giving her tiers of loot. In terms of specifics here, D1 exotic No Land Beyond is showing up.
There was a new focus on a Kepler-specific mechanic using Dark Matter mixed with our late. Part puzzle, part combat. An example is a guardian turning into a Samus Aran energy ball that can zap energy but go into small spaces for flanking and puzzles. A void ability lets you teleport through laser walls. Strand 'matter morph' lets you move/build objects. A lot of this is puzzle stuff, but also with combat uses.
More generally, the idea is that Destiny 2 has too many barriers to play and know what to do, so the new 'portal' screen replaces the planet destination screen to more easily get into activities that are clearly labeled, very quickly, plus reward previews.
Destiny 2 Bungie 'Major updates' will be Into the Light scale, not a full season. There are technically season names that span the entire duration of the expansion, so six months, but not formatting like a traditional season. One example is returning to the Plaguelands for Ash and Iron. One activity, one exotic mission.
Destiny 2 is finally adding its shooting range back with actual scoreboards and such. They're making a new sparrow that can actually shoot things, available before the season in its Brigs vs. Tank event.
Renegades is a very clear homage to Star Wars in addition to being an important part of the Fate saga. This would almost have to be a licensed collaboration given how 'inspired' it is.
I'm still processing all this, but it didn't strike me as some new crazy era of Destiny. It really only is plot-wise, it seems. But we'll know more in two months and we can see how it feels then.
Follow me on Twitter , YouTube , Bluesky and Instagram .
Pick up my sci-fi novels the Herokiller series and The Earthborn Trilogy .
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Sir Rod Stewart 'devastated' after cancelling more US concerts as he recovers from flu
Sir Rod Stewart says he is devastated to have to cancel a series of US concerts, blaming lingering flu for the decision. It affects four shows in Nevada, along with a further two in California, which he plans to reschedule. They were due to take place over the next eight days. "So sorry my friends. I'm devastated and sincerely apologise for any inconvenience to my fans. I'll be back on stage and will see you soon," he wrote in a message on Instagram. , 80, has been struggling to recover from flu and this week had already cancelled two concerts at Caesars Palace, Las Vegas. On Wednesday, he disclosed that his doctor had "ordered" him to take "a bit more rest". The star is in the midst of his epic One Last Time Tour. Sir Rod, who was recently put on vocal rest, is due to later this month. In May, he was presented with a lifetime achievement award at the American Music Awards (AMAs). In a sign of how seriously the singer takes his health, last month he was also spotted in Italy attempting to avoid conversations to preserve his voice. He wore a message attached to a lanyard which read: "Sorry. Cannot talk. Having vocal rest." In 2024, he promised he would not retire but confirmed his 2025 European and North American shows would bring an end to his "large-scale world tours". Read more from Sky News: The performer, best known for songs including Da Ya Think I'm Sexy?, Every Beat Of My Heart, and Maggie May, said he plans to focus on more intimate venues instead. Sir Rod has faced other health challenges in the past. In May 2000, he was diagnosed with thyroid cancer and had surgery. In 2017, he underwent successful treatment for prostate cancer.
Yahoo
38 minutes ago
- Yahoo
Miley Cyrus Explains How She Used to Hide All of the Money She Spent on Drugs from Her Accountant
Miley Cyrus recalls the days of hiding her drug purchases from those around her The former Disney star visited The Ringer's Every Single Album podcast where she discussed her drug use during Miley Cyrus & Her Dead Petz era She has also openly discussed her sobriety journeyMiley Cyrus is opening up about her past drug use — and how she used to keep it a secret from those around her, specifically her accountant. The music artist, 32, got candid while taking a deep dive into where she was mentally for each of her albums like Bangerz and Endless Summer Vacation, for the Friday, June 6 episode of The Ringer's Every Single Album podcast. During their discussion of her 2015 album, Miley Cyrus & Her Dead Petz, the former Disney star revealed where some of her money went without her accountant's knowledge. 'The drugs were the biggest cost, which to hide those from my accountant, we called them vintage clothes,' Cyrus said. The 'Flowers' singer continued, 'And so she would get these checks. That happens on touring all the time.' Cyrus said over time her accountant would wonder about the "vintage clothes" costs but she always made sure to keep her purchases discreet. 'And every time she saw me, she'd be like, 'Where's that, like, $15,000 original John Lennon T-shirt that you bought?' It's like, 'Oh, it's upstairs,' ' she said. 'We just really want to protect it. It's really delicate. The fabric got to take care of it. So I bought a lot of vintage clothes that year,' Cyrus added. Continuing to reflect on Miley Cyrus & Her Dead Petz, the 'We Can't Stop' singer admitted she's grateful for how far she's come since that period in her life. 'I'm so glad I survived that time in my life," Cyrus said. "I would definitely not encourage anyone else to go this hard, but the fact that I got through it, I'm very glad I got to do it.' Cyrus has been open about her sobriety throughout the passing years. In a 2017 interview with Billboard, she said she was 'evolving' after giving up marijuana. 'I haven't smoked weed in three weeks, which is the longest I've ever [gone without it],' she said at the time. 'I'm not doing drugs, I'm not drinking, I'm completely clean right now! That was just something that I wanted to do.' She later spoke to Rolling Stone for the magazine's January 2021 cover story after she "fell off" and started drinking during the pandemic. Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. "[I] haven't done drugs in years. Honestly, I never try to, again, be a fortune-teller. I try to not be naive," Cyrus said at the time. "Things f—--- happen. But from sitting here with you right now, I would say it would have to be a cold day in hell for me to relapse on drugs." If you or someone you know is struggling with substance abuse, please contact the SAMHSA helpline at 1-800-662-HELP. Read the original article on People
Health Line
41 minutes ago
- Health Line
Ask the Expert: Should I have Biomarker Testing – and Would it Help?
Biomarker testing in colorectal cancer can help assess inherited risk and identify characteristics that may influence the disease's growth, spread, and response to treatment. Colorectal cancer (CRC) starts in the colon or rectum of the large intestine. Your doctor may refer to it as 'colon cancer' or 'rectal cancer,' depending on where the cancer develops first, but both of these diagnoses are included under the banner of CRC. CRC is treatable, and biomarker testing is a part of precision medicine in your comprehensive treatment plan. Biomarker testing in CRC can help detect cancer in its earliest, most treatable stages. It can also provide important details about cancer after a diagnosis that influence treatment and outcomes. Dr. Smitha Krishnamurthi, a gastrointestinal oncology specialist with the Cleveland Clinic, talks with Healthline about biomarker testing and who it's recommended for. What is biomarker testing? Biomarker testing refers to testing of the colorectal cancer to find out if there are certain changes in the cancer's genes and proteins that could impact prognosis [outlook] and treatment. What are the most common biomarkers, and what do they show? Biomarkers in CRC measure a variety of different biological processes and states. Each biomarker provides important details about the cancer's growth, spread, or treatment response. DNA mismatch repair Hospital pathology labs now commonly test all initial biopsies or surgical specimens of colorectal cancer for the presence of DNA mismatch repair proteins. This is done via immunohistochemistry (IHC) staining of the slides to look for [the] expression of four mismatch repair proteins: MLH1, PMS2, MSH2, and MSH6. If one or two of these proteins are missing, then the cancer has deficient DNA mismatch repair. Microsatellite instability (MSI) This is a polymerase chain reaction (PCR) or next-generation sequencing (NGS) test [that looks] for abnormalities in microsatellite regions of the cancer DNA. The test can be done on a tumor specimen or blood (liquid biopsy). Microsatellites are short, repeated sequences of DNA. If the cancer has [atypical] DNA mismatch repair, errors will appear in microsatellite regions of DNA in the form of missing bases or extra bases added to the DNA sequence. RAS gene mutations (mutations in KRAS and NRAS genes) This testing can be performed by PCR or NGS testing of the tumor or NGS testing of blood (liquid biopsy). RAS is a very important oncogene, meaning that it is a gene that, when mutated, drives cancer cell proliferation and survival. Mutations in RAS genes are found in up to 50% of colorectal cancers. BRAF V600E gene mutation This testing can be performed by PCR or NGS testing of the tumor or NGS testing of blood (liquid biopsy). The BRAF V600E protein can also be detected by IHC. BRAF is another oncogene, so when it is mutated, it leads to cancer cell proliferation and survival. BRAF V600E mutations occur in about 8% to 10% of colorectal cancers and are more common in right-sided cancers. HER2 protein overexpression by IHC or gene amplification by NGS HER2 is another oncogene — gene amplification leads to [the] overexpression of the HER2 protein. Overexpression of HER2 leads to increased signaling via the epidermal growth factor receptor pathway, leading to cancer cell proliferation and survival. PIK3CA PIK3CA is another oncogene. Mutations in PIK3CA and a related gene, PIK3R1, lead to cancer cell proliferation and survival. Mutations in PIK3CA and PIK3R1 are typically found via NGS. PTEN PTEN is a tumor suppressor gene, [which typically] suppresses cancer growth. When the PTEN gene is mutated, the protein is not expressed, and that leads to [the] proliferation of cancer. PTEN gene mutations are typically found via NGS. Who should have biomarker testing done? All patients with colorectal cancer should have testing of their cancer for DNA mismatch repair (or microsatellite instability) soon after diagnosis. This is important for patients with cancers of all stages. Patients with early stage colorectal cancer should have testing of their cancers for mutations in PIK3CA, PTEN, and PIK3R1 by the time they finish adjuvant treatment or after surgery if [they're] not having adjuvant treatment. Patients with metastatic colorectal cancer should have next-generation sequencing of the cancer soon after diagnosis, as the results may impact the initial systemic treatment. The NGS results are also useful for identifying clinical trial eligibility. Comorbidities will not affect the results of these biomarkers, so they should not affect the timing and decision making about ordering these tests. How does biomarker testing help the treatment and outcome of a diagnosis? Biomarkers can impact your treatment choices and outcomes. They can help doctors decide which medications will be the most effective, identify inherited features in cancer, and determine if adjuvant or additional therapies would improve outcomes. Immunotherapy responsiveness It is critical to know if a cancer has deficient DNA mismatch repair (dMMR) or high microsatellite instability (MSI-H) because these cancers can respond dramatically to immunotherapy in the early stage and metastatic settings. For example, patients with rectal cancer that is dMMR or MSI-H may have a complete clinical response with immunotherapy and may be able to avoid radiation and surgery. Thus, this testing needs to be done early, before treatment starts. Identifying Lynch syndrome Another important reason for testing for dMMR or MSI-H is to identify cancers caused by Lynch syndrome. Lynch syndrome is the most common type of inherited colorectal cancer and is caused by germline mutations in the genes that code for the DNA mismatch repair proteins or in another related gene called EPCAM. Most cancers with deficient mismatch repair or MSI-H are not caused by Lynch syndrome and occur sporadically. We don't want to miss patients with Lynch syndrome, however, because they can benefit from counseling about [the] prevention of Lynch syndrome-related cancers such as uterine cancer, ovarian cancer, and gastric cancer, in addition to colorectal cancer. When a patient is diagnosed with Lynch syndrome, family members can then be tested to see if they have Lynch syndrome. Recommendations for cancer screening at early stages are made for individuals with Lynch syndrome, and early screening can be lifesaving. Identifying treatment resistance Mutations in KRAS and NRAS make cancers resistant to anti-epidermal growth factor receptor therapy. Cancers with KRAS G12C mutations can be treated with a regimen that targets this mutation (adagrasib plus cetuximab or sotorasib plus panitumumab). There are also many clinical trials now studying RAS gene inhibitors in patients with metastatic colorectal cancer that have been previously treated. Cancers with BRAF V600E tend to be aggressive and less sensitive to chemotherapy. There is a Food and Drug Administration (FDA)-approved regimen targeting BRAF V600E (encorafenib plus cetuximab) in metastatic colorectal cancer that improves survival when added to first-line FOLFOX chemotherapy. It also improves survival as a second-line treatment after chemotherapy. Greater response to targeted and adjuvant therapy Metastatic colorectal cancers that demonstrate [the] overexpression or gene amplification of HER2 can be treated with a targeted regimen of tucatinib plus trastuzumab after initial chemotherapy. Another targeted treatment available for metastatic colorectal cancers that overexpress HER2 by IHC is trastuzumab deruxtecan. Patients with early stage colorectal cancer with mutations in the PIK3CA, PIK3R1, or PTEN genes should be treated with aspirin 160 milligrams daily for 3 years after adjuvant therapy or after surgery if [they're] not having adjuvant therapy. The ALASCCA trial, presented at ASCO GI [American Society of Clinical Oncology – Gastrointestinal Cancer] in 2025, compared a placebo to aspirin in this patient population and found that aspirin significantly lowered the rate of cancer recurrence at 3 years. This is rather new data. Oncologists are starting to order NGS testing for patients with early stage cancers in order to obtain this biomarker information. What should you ask your doctor? It's always OK to ask your doctor about biomarker testing and what it means for you. Important questions to consider include: Is my cancer dMMR/MSI-H? Am I a candidate for immunotherapy? Patients with early stage colorectal cancer should ask if aspirin therapy will be recommended based on biomarker testing. Patients with metastatic colorectal cancer should ask for the results of RAS/BRAF/HER2 testing and overall NGS testing results.
